Benign Prostatic Hyperplasia Clinical Trial
Official title:
An Open Label, Single Center, Pilot Study to Evaluate the Safety and Effectiveness of OCL 503 in Prostate Artery Embolization for the Treatment of Men With Benign Prostatic Hypertrophy
Verified date | August 2018 |
Source | IMBiotechnologies Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective, pilot, open-label, uncontrolled, non-randomized safety and effectiveness study of OCL 503 in men with BPH.
Status | Completed |
Enrollment | 10 |
Est. completion date | May 2018 |
Est. primary completion date | May 2018 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 51 Years and older |
Eligibility |
Inclusion Criteria: - Patient has received a diagnosis of BPH with moderate to severe LUTS, as determined by IPSS - Patient is greater than 50 years of age - Patient has had a pelvic examination within the past 6 months - Patient has been refractory to medical therapy for the last 6 months, or has refused medical therapy - Patient has a Qmax below 15 mL/s or acute urinary retention - Prostate is larger than 40 cubic centimetres - Patient is willing and able to provide written, informed consent Exclusion Criteria: - Known malignancy - Serum PSA > 10 ng/mL at screening - Advanced atherosclerosis and tortuosity of the iliac arteries - Prior transurethral resection of the prostate (TURP) - Post void retention (PVR) > 250 mL - Chronic use of metronidizole - Phytotherapy for BPH within last two weeks of screening visit - Secondary renal insufficiency due to prostatic obstruction - Chronic renal failure (GSR < 60) - Large bladder diverticula or bladder stones - Claustrophobia or other contraindications related to performing MRI - Compromised hematopoietic function - Anaphylactic reaction to drug or anesthetic, allergic reaction to iodine or contrast media - Investigational drug or experimental therapy in the past 4 weeks - Abnormal coagulation profile - Allergy to bovine collagen |
Country | Name | City | State |
---|---|---|---|
Canada | University of Alberta Hospital | Edmonton | Alberta |
Lead Sponsor | Collaborator |
---|---|
IMBiotechnologies Ltd. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety of OCL 503 as measured by Adverse Events reporting. | Measurement of device related adverse events post embolization of the prostatic vasculature, at 30 days. | 12 months | |
Primary | International Prostate Symptom Score (IPSS) | Measurement of IPSS at 12 months post embolization of the prostatic vasculature with OCL 503. | 12 months | |
Secondary | Tissue Response | Measurement in the change in size of the prostate by MRI at 12 months post embolization of the prostatic vasculature with OCL 503. | 12 months | |
Secondary | Uroflowmetry | Measurement of Qmax, post-voiding bladder retention (PVR) at 12 months post embolization of the prostatic vasculature with OCL 503. | 12 months | |
Secondary | International Index of Erectile Function (IIEF) | Measurement of IIEF by questionnaire at 12 months post embolization of the prostatic vasculature using OCL 503. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04807296 -
Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP)
|
N/A | |
Recruiting |
NCT05574244 -
Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction
|
N/A | |
Recruiting |
NCT04288427 -
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
|
N/A | |
Not yet recruiting |
NCT04245566 -
Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH
|
Phase 3 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Completed |
NCT03246880 -
Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients
|
Phase 3 | |
Completed |
NCT02206243 -
Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
|
||
Completed |
NCT02283684 -
GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT
|
Phase 4 | |
Completed |
NCT01454349 -
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)
|
Phase 1/Phase 2 | |
Completed |
NCT01438775 -
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
Completed |
NCT01139762 -
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
|
Phase 3 | |
Completed |
NCT01152190 -
A Study in Benign Prostatic Hyperplasia
|
Phase 3 | |
Active, not recruiting |
NCT00400894 -
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
|
N/A | |
Unknown status |
NCT00381108 -
Study of the Effects of Pomegranate Tablets on Enlarged Prostates
|
Phase 1 | |
Completed |
NCT00224133 -
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
|
Phase 3 | |
Completed |
NCT00701779 -
Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia
|
Phase 4 | |
Terminated |
NCT02962674 -
To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH.
|
N/A | |
Active, not recruiting |
NCT05415748 -
Deprescribing Tamsulosin in Older Men
|
Phase 4 | |
Recruiting |
NCT04853914 -
Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound.
|
N/A | |
Completed |
NCT04831476 -
Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin . PROSPERITY Group of Studies (I&II)
|